News - Lauxera Capital Partners

NEWS

News

All
Lauxera
Caresyntax
Lumicks
OSPI
Lifen
Matrix Requirements
Verdot
OrganOx
BioLamina

Article - Impact

March 15, 2024

IMPACT AND FINANCIAL RETURNS: A WINNING COMBINATION

Article - video-Lauxera-Check

March 9, 2024

Pierre Moustial on BFM Business – Check-up Santé

video-lauxera-imagine

March 4, 2024

Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial

Article 1-Institut Imagine

October 10, 2023

Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases

Article 2_OSPI

October 2, 2023

OSPI wants to optimize the use of hospital data with AI

article 3_Cr├®ation OSPI

September 26, 2023

Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking

article 5-BioLamina

September 12, 2023

Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina

Article 6-OrganOx

July 17, 2023

Lauxera Capital Partners has led a £25m growth investment into OrganOx

Article 4-Caresyntax

May 3, 2023

Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program

Article 8_Verdot

September 13, 2022

Purification: Auvergne, France-based Verdot Ips² changes hands

Article 9_MAtrix

June 16, 2022

Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements

Article 7_Final Closing

February 8, 2022

Lauxera Capital Partners – Press release – Final closing

Article 11-Lifen

November 16, 2021

Leading MedTech Lifen raises €50M

Article 10_Pierre Moustial

October 11, 2021

Pierre Moustial Interview

Article 13_Caresyntax

September 16, 2021

Caresyntax Extends Series C to Total Raise of $130 million

Article 12_PSIH

September 14, 2021

Press Release Groupe PSIH

Article 14_Caresyntax

April 29, 2021

Sifted – Caresyntax secures $100m for AI hospital operating tech

Article 15_Caresyntax

April 28, 2021

Fierce Healthcare – Caresyntax hauls in $100m to expand

Article 16-Lumicks

April 27, 2021

Fierce Biotech – Lumicks snags £93M for its molecular tweezers and cell therapy hardware